Related Experiment Videos

pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis

B B Aggarwal1, K Totpal, F Ali-Osman

  • 1Department of Clinical Immunology and Biological Therapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030.

FEBS Letters
|May 30, 1994
PubMed

Insights

Oncogenic tyrosine kinase pp60v-src overexpression confers resistance to tumor necrosis factor (TNF) in tumor cells. Interferon-gamma can reverse this resistance, suggesting pp60v-src

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Cellular resistance to tumor necrosis factor (TNF) is a significant challenge in cancer therapy.
  • The molecular mechanisms underlying TNF resistance are not fully elucidated.
  • Previous studies linked HER2/neu/erb B2 oncogene overexpression to TNF resistance.

Purpose of the Study:

  • To investigate the role of the oncogenic tyrosine kinase pp60v-src in cellular resistance to TNF.
  • To compare the resistance mechanisms induced by pp60v-src with those induced by HER2.
  • To explore potential strategies to overcome pp60v-src-mediated TNF resistance.

Main Methods:

  • Transfection of cells with the pp60v-src oncogene.
  • Assessment of TNF receptor expression levels.
  • Measurement of intracellular glutathione levels.
  • Evaluation of the effect of interferon-gamma on TNF resistance.

Main Results:

  • Overexpression of pp60v-src induced cellular resistance to TNF.
  • Unlike HER2, pp60v-src did not down-modulate TNF receptors.
  • pp60v-src transfection led to decreased intracellular glutathione levels.
  • Interferon-gamma abrogated the pp60v-src-induced TNF resistance.

Conclusions:

  • Overexpression of the pp60v-src oncogene is a novel mechanism contributing to tumor cell resistance to TNF.
  • pp60v-src-induced TNF resistance involves decreased intracellular glutathione, distinct from HER2-mediated resistance.
  • Interferon-gamma represents a potential therapeutic approach to sensitize tumors to TNF therapy when pp60v-src is overexpressed.

Related Concept Videos